Compare Novo Nordisk A/S (NVO) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Zillow Group Inc Class C — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: Novo Nordisk A/S is far larger — about 25.1× Zillow Group Inc Class C's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Zillow Group Inc Class C for 38 Days on average.
| NVO | Z | |
|---|---|---|
Market Cap | $165.31B | $6.59B |
Volume | 11,432,838 | 9,134,294 |
Sector | Health | Media |
52-Week High | $63.98 | $78.04 |
52-Week Low | $35.29 | $27.13 |
Typical Hold Time | 116 Days | 38 Days |
Enterprise Value | $179.56B | $6.47B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Zillow Group (Z) trades at $29.17, up 6.93% with mixed technical signals showing bullish oscillators but bearish moving averages. The company shows improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability with $23M net income. Recent developments include AI integration in real estate services and resolution of FTC antitrust litigation, positioning the company for continued platform expansion.
The stock presents a compelling opportunity with analyst consensus target of $60.33 representing 107% upside, though high P/E of 126.83 reflects growth expectations. Key risks include mortgage rate sensitivity and housing market cyclicality, while the shift to an integrated transaction platform could drive long-term value if execution succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
